Showing results (101-110 of 119) with videos related to
Sort By:
Pageof 12
International Journal of Clinical Oncology|January 23, 2021
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON studyTaiga Otsuka, Tsuyoshi Shirakawa, Mototsugu Shimokawa, et al.Pancreas|August 4, 2021
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study)Shiho Arima, Machiko Kawahira, Mototsugu Shimokawa, et al.Anticancer Research|July 7, 2021
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel Versus FOLFIRINOX for Recurrent Pancreatic Cancer After ResectionHiroki Taguchi, Taiga Otsuka, Mototsugu Shimokawa, et al.Oncology|October 4, 2022
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON StudyJunichi Nakazawa, Nobuhiro Tsuruta, Mototsugu Shimokawa, et al.Scientific Reports|November 8, 2023
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancerMasaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, et al.Scientific Reports|May 31, 2023
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxelTsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, et al.Journal of Geriatric Oncology|July 3, 2021
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study)Futa Koga, Yasunori Kawaguchi, Mototsugu Shimokawa, et al.Therapeutic Advances in Medical Oncology|February 24, 2025
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)Tomonori Araki, Kohei Hayashi, Mototsugu Shimokawa, et al.Asia-Pacific Journal of Clinical Oncology|November 4, 2025
Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 StudyAtsuko Kakihara, Shigeyuki Takeshita, Mototsugu Shimokawa, et al.BMC Cancer|October 22, 2025
Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results from the NAPOLEON-2 studyKazuo Nishikawa, Taiga Otsuka, Mototsugu Shimokawa, et al.Pageof 12